Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts

Abstract

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia. obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

1 . A method for treating panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive disorders, social phobia, posttraumatic stress disorder, acute stress indication and/or generalized-anxiety disorder in a patient comprising administering to said patient an effective amount of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof. 
   
   
       2 . Pharmaceutical preparation for the treatment of sub-type anxiety disorders according to  claim 1 , characterized in that it contains at least 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts. 
   
   
       3 . A method for treating a bipolar disorder, mania or both in a patient comprising administering to said patient an effective amount of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof. 
   
   
       4 . A method according to  claim 3 , wherein said patient is suffering from mania. 
   
   
       5 . A method for treating dementia in a patient comprising administering to said patient an effective amount 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof. 
   
   
       6 . A method for treating substance-related disorders in a patient comprising administering to said patient an effective amount of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof. 
   
   
       7 . A method for treating a sexual dysfunction in a patient comprising administering to said patient an effective amount of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof. 
   
   
       8 . A method for treating an eating disorder, anorexia or obesity in a patient comprising administering to said patient an effective amount of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof. 
   
   
       9 . A method for treating fibromyalgia in a patient comprising administering to said patient an effective amount of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt. 
   
   
       10 . A method according to  claim 1 , wherein said patient is administered the pharmacologically acceptable salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       11 . A method according to  claim 1 , wherein said patient is administered the pharmacologically acceptable salt 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       12 . A method according to  claim 3 , wherein said patient is administered the pharmacologically acceptable salt 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       13 . A method according to  claim 4 , wherein said patient is administered the pharmacologically acceptable salt 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       14 . A method according to  claim 5 , wherein said patient is administered the pharmacologically acceptable salt 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       15 . A method according to  claim 6 , wherein said patient is administered the pharmacologically acceptable salt 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       16 . A method according to  claim 7 , wherein said patient is administered the pharmacologically acceptable salt 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       17 . A method according to  claim 8 , wherein said patient is administered the pharmacologically acceptable salt 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       18 . A method according to  claim 9 , wherein said patient is administered the pharmacologically acceptable salt 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride. 
   
   
       19 . A method according to  claim 1 , wherein 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is administered to said patient in a daily amount of 0.01-10 mg/kg of body weight. 
   
   
       20 . A method according to  claim 19 , wherein 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride is administered to said patient in a daily amount of 0.01-10 mg/kg of body weight.